findmyKOL
Clinical trialNCT01145430CompletedPhase 1Interventional

Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer

SponsorNational Cancer Institute (NCI)Enrollment45Estrogen Receptor NegativeHER2/Neu NegativeMale Breast CarcinomaProgesterone Receptor NegativeRecurrent Breast CarcinomaRecurrent Fallopian Tube Carcinoma+4 more conditions
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase I trial studies the side effects and the best dose of veliparib when given together with pegylated liposomal doxorubicin hydrochloride in treating patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that has come back after a period of improvement, or breast cancer that has spread to other parts of the body. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as liposomal doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib together with liposomal doxorubicin hydrochloride may kill more tumor cells.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Columbia University/herbert Irving Cancer Center

    New York, New York, United States

  • Laura and Isaac Perlmutter Cancer Center at Nyu Langone

    New York, New York, United States

  • Mount Sinai Hospital

    New York, New York, United States

  • Weill Medical College of Cornell University

    New York, New York, United States

  • Montefiore Medical Center - Moses Campus

    The Bronx, New York, United States

  • Montefiore Medical Center-Einstein Campus

    The Bronx, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Doxorubicin →Veliparib →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
1 Jun 2010
Primary completion
23 May 2017
Completion
—
Last update posted
22 Dec 2017
Registered enrollment
45
Registry id
NCT01145430
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.